Managing tuberculosis in patients with diabetes mellitus: Why we care and what we know

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 8, 2012, Pages 863-868

  Jeon, Christie Y ^a   Murray, Megan B ^b,c   Baker, Meghan A ^c,d  

^a Howard Hughes Medical Institute   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antibiotic treatment; diabetes mellitus; glucose control; tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE;

BACTERICIDAL ACTIVITY; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; GLYCEMIC CONTROL; HUMAN; LOWEST INCOME GROUP; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RELAPSE; REVIEW; SCREENING TEST; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MANAGEMENT; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; RECURRENCE; RIFAMPIN; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 84867044910     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.75     Document Type: Review

References (45)

1. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293(22), 2767-2775 (2005).
2. WHO. Global Tuberculosis Control: WHO Report 2010. WHO, Geneva, Switzerland (2010).
3. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc. Sci. Med. 68(12), 2240-2246 (2009).
4. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311-321 (2011).
5. Leung CC, Lam TH, Chan WM et al. Diabetic control and risk of tuberculosis: a cohort study. Am. J. Epidemiol. 167(12), 1486-1494 (2008).
6. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin. Infect. Dis. 54(6), 818-825 (2012).
7. Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 9, 81 (2011).
8. Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am. J. Respir. Cell Mol. Biol. 37(5), 518-524 (2007).
9. Chang FY, Shaio MF. Decreased cellmediated immunity in patients with non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 28(2), 137-146 (1995).
10. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am. J. Med. 72(3), 439-450 (1982).
11. Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect. Immun. 28(1), 127-131 (1980).
12. Sugawara I, Mizuno S. Higher susceptibility of Type 1 diabetic rats to Mycobacterium tuberculosis infection. Tohoku J. Exp. Med. 216(4), 363-370 (2008).
13. Sugawara I, Yamada H, Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. Tohoku J. Exp. Med. 204(2), 135-145 (2004).
14. Vallerskog T, Martens GW, Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J. Immunol. 184(11), 6275-6282 (2010).
15. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 5(7), e152 (2008).
16. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin. Infect. Dis. 54(6), 818-825 (2012).
17. Jeon CY, Harries AD, Baker MA et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop. Med. Int. Health 15(11), 1300-1314 (2010).
18. Alisjahbana B, van Crevel R, Sahiratmadja E et al. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int. J. Tuberc. Lung Dis. 10(6), 696-700 (2006).
19. Golsha R, Rezaei SR, Shafiee A, Najafi L, Dashti M, Roshandel G. Pulmonary tuberculosis and some underlying conditions in Golestan Province of Iran, during 2001-2005. J. Clin. Diag. Res. 3(1), 1302-1306 (2009).
20. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 27(7), 1584-1590 (2004).
21. Restrepo BI, Camerlin AJ, Rahbar MH et al. Cross-sectional assessment reveals high diabetes prevalence among newlydiagnosed tuberculosis cases. Bull. World Health Organ. 89(5), 352-359 (2011).
22. Gupta S, Shenoy VP, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J. Infect. Public Health 4(3), 140-144 (2011).
23. Wang CS, Yang CJ, Chen HC et al. Impact of Type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol. Infect. 137(2), 203-210 (2009).
24. Chiang CY, Lee JJ, Yu MC, Enarson DA, Lin TP, Luh KT. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int. J. Tuberc. Lung Dis. 13(1), 105-111 (2009).
25. Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber. Lung Dis. 77(2), 124-129 (1996).
26. Ramarokoto H, Randriamiharisoa H, Rakotoarisaonina A et al. Bacteriological follow-up of tuberculosis treatment: a comparative study of smear microscopy and culture results at the second month of treatment. Int. J. Tuberc. Lung Dis. 6(10), 909-912 (2002).
27. Nijland HM, Ruslami R, Stalenhoef JE et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and Type 2 diabetes. Clin. Infect. Dis. 43(7), 848-854 (2006).
28. Ruslami R, Nijland HM, Adhiarta IG et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with Type 2 diabetes. Antimicrob. Agents Chemother. 54(3), 1068-1074 (2010).
29. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin. Pharmacokinet. 44(3), 221-235 (2005).
30. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin. Pharmacol. Ther. 76(3), 239-249 (2004).
31. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69(6), 400-406 (2001).
32. Chang JT, Dou HY, Yen CL et al. Effect of Type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrugresistance. J. Formos. Med. Assoc. 110(6), 372-381 (2011).
33. Pfaffenberg R, Jahler H. Isoniazid & recurrence of tuberculosis in diabetics. Z. Tuberk. 111(3-4), 167-173 (1958).
34. WHO, International Union Against Tuberculosis and Lung Disease. Collaborative Framework for Care and Control of Tuberculosis and Diabetes. WHO, Geneva, Switzerland (2011).
35. Blumberg HM, Burman WJ, Chaisson RE et al.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4), 603-662 (2003).
36. WHO. Stop TB Dept. Treatment of Tuberculosis: Guidelines. WHO, Geneva, Switzerland (2010).
37. Pacific Island TB Controllers Association (Pitca). USAPI standards for the management of tuberculosis and diabetes. USAPI Standards for the Management of Tuberculosis and Diabetes 2012. March 2011.
38. Lesnichii AV, Karpina LZ. Experience with the chemoprophylaxis of pulmonary tuberculosis in diabetes mellitus patients. Probl. Tuberk. 47(12), 1-3 (1969).
39. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am. J. Respir. Crit. Care Med. 172(9), 1169-1227 (2005).
40. Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin. Infect. Dis. 45(4), 436-438 (2007).
41. Allain TJ, van Oosterhout JJ, Douglas GP et al. Applying lessons learnt from the 'DOTS' Tuberculosis Model to monitoring and evaluating persons with diabetes mellitus in Blantyre, Malawi. Trop. Med. Int. Health 16(9), 1077-1084 (2011).
42. World Health Organization Western Pacific Region. Federated States of Micronesia (Pohnpei) NCD Risk Factors STEPS Report. Federated States of Micronesia (Pohnpei) NCD Risk Factors STEPS Report (2008).
43. Harries AD, Lin Y, Satyanarayana S et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int. J. Tuberc. Lung Dis. 15(11), 1436-1444, i (2011).
44. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl. 1), S11-S63 (2012).
45. Gnanasan S, Ting KN, Wong KT, Mohd Ali S, Muttalif AR, Anderson C. Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care. Int. J. Clin. Pharm. 33(1), 44-52 (2011).